VOLUME 21 - NUMBER 3 / July - September (Review articles / Artículos de revisión)
Christian O. Ramos-Peñafiel, Hematology Department, Hospital General de México Dr. Eduardo Liceaga; National Research Department, Consejo Nacional de Ciencia y Tecnología (Conacyt); Mexico City, Mexico
Erika A. Rosas-González, Research Department in Clinical Nutrition, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Irma Olarte-Carrillo, Hematology Department, Hospital General de México Dr. Eduardo Liceaga; School of Medicine, UNAM; 6Molecular Biology Laboratory, Hospital General de México Dr. Eduardo Liceaga. Mexico City, Mexico
Mónica P. Bejarano-Rosales, Research Department in Clinical Nutrition, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Karolina Álvarez-Altamirano, Research Department in Clinical Nutrition, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Vanessa Fuchs-Tarlovsky, National Research Department, Consejo Nacional de Ciencia y Tecnología (Conacyt); Research Department in Clinical Nutrition, Hospital General de México Dr. Eduardo Liceaga; Mexico City, Mexico
Carlos Martínez-Murillo, Hematology Department, Hospital General de México Dr. Eduardo Liceaga, Mexico City, Mexico
Adrián Santoyo-Sánchez, Hematology Department, Hospital General de México Dr. Eduardo Liceaga; School of Medicine, UNAM; Mexico City, Mexico
Adolfo Martínez-Tovar, Hematology Department, Hospital General de México Dr. Eduardo Liceaga; Molecular Biology Laboratory, Hospital General de México Dr. Eduardo Liceaga. Mexico City, Mexico
Cancer is a significant cause of death worldwide. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection is spreading rapidly globally. Information on coronavirus disease 2019 (COVID-19) and its complications in cancer patients are still limited. It is relevant to consider that some chemotherapeutic agents have secondary immunosuppressive effects. Approximately 35% of hematologic cancer patients develop pneumonia caused by community respiratory viruses. People older than 65 years-old or with severe neutropenia or lymphopenia are at higher risk. Cancer patients with pneumonia infected by parainfluenza virus showed a higher risk of mortality compared to non-cancer patients (p < 0.05; 12.3% vs. 3.8%) or coronavirus infections (p < 0.01; 24% vs. 30%). Complications associated with SARS-COV2 infection in cancer patients are limited to descriptive studies, with those who received myeloablative, immunosuppressive or monoclonal antibody therapies being more susceptible.
Keywords: SARS-CoV-2. COVID-19. Cancer. Chemotherapy.
